Amanta Healthcare Limited has announced its audited financial results for the quarter and year ended March 31, 2026. The company reported a net profit of INR 15 Cr for the fiscal year 2026, marking a 42% increase from INR 11 Cr in the previous year. Revenue from operations for the year stood at INR 288 Cr, compared to INR 275 Cr in FY25.

For the quarter ended March 31, 2026, the company recorded a net profit of INR 5.5 Cr, while revenue from operations was INR 77 Cr. The board approved the financial results during its meeting held on May 19, 2026.

Financial Performance Summary

The company's total income for FY26 rose to INR 291 Cr from INR 276 Cr in the previous year. Total expenses for the year increased to INR 228 Cr. Profit before tax for the year was INR 21 Cr, up from INR 15 Cr in FY25. EBITDA for the year increased 6.06% YoY to INR 63 Cr, with margins at 22%.

Operational Highlights

Earnings per share (EPS) for the year improved to INR 4.33 from INR 3.71 in the previous year. The company's cash and cash equivalents as of March 31, 2026, were reported at INR 8,101.03 Cr, a significant increase from INR 22.06 Cr in the prior year. This increase was primarily driven by proceeds from the Initial Public Offer (IPO) completed during the year.

The board meeting also reviewed the utilization of IPO proceeds. The company had raised INR 12,600 lakhs through its IPO, with INR 7,353.25 lakhs utilized towards capital expenditure and general corporate purposes as of March 31, 2026. The company reduced total borrowings by over INR 30 Cr, primarily through the full repayment of all outstanding Non-Convertible Debentures (NCDs).

Business Outlook

During the post-results conference call, management highlighted that the SteriPort platform contributes nearly 42% of revenue from operations. The company is expanding capacity from 6.6 crore bottles per year to roughly 12 crore bottles per year to capture the growing market for two-port systems, which are preferred in therapies like oncology and critical care. The expansion is expected to be operational by June 20, 2026.

Management also noted that the debt-to-equity ratio has improved from 3x to nearly 1x over the last three years. A 10.8 megawatt captive solar power project is under implementation and expected to be commissioned soon, which is anticipated to reduce power costs by approximately INR 75 lakh per month from FY27 onwards. The company expects EBITDA margins to improve to between 24% and 25% going forward, driven by the new SteriPort capacity and cost optimization initiatives.

The Board of Directors of amanta healthcare has approved the appointment and re-appointment of statutory auditors for the company. The decisions were taken during a meeting held on May 19, 2026, pursuant to the recommendations of the Audit Committee.

The Board appointed M/s. Kashyap R. Mehta & Partners, Practicing Company Secretaries, as the Secretarial Auditor for a term of five consecutive years. This term commences from the financial year 2026-27 and continues until the financial year 2030-31. However, this appointment is subject to the approval of shareholders at the ensuing Annual General Meeting.

In addition to the new appointment, the Board approved the re-appointment of M/s. Parikh Shah & Associates, Chartered Accountants, as the Internal Auditor of the company for the financial year 2026-27. The firm, incorporated on May 29, 2003, provides statutory and tax audits, internal audits, and management advisory services.

Furthermore, M/s Y S THAKAR & Co., Cost Accountants, were re-appointed as the Cost Auditor for the financial year 2026-27. Established in 2011, the firm is a leading partnership of Cost and Management Accountants in Gujarat with a client base exceeding 120 and a track record of filing over 2000 cost audit reports.

Auditor Appointments Summary

The company confirmed that there are no relationships to disclose between the Directors inter se, the Manager, and the Key Managerial Personnel (KMPs) regarding these appointments.